Dr. Lerner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave 3rd FL
Moakley Hematologyoncology
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Summary
- Dr. Adam Lerner is an oncologist in Boston, MA. He received his medical degree from Yale University School of Medicine and has been in practice 34 years, primarily at Boston University and Boston Medical Center. He has carried out translational research on cyclic nucleotide phosphodiesterase inhibitors as well as on a focal adhesion complex adapter protein, BCAR3/AND-34. He specializes in hematologic oncology, cutaneous oncology and soft tissue sarcomas.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1991
- Boston University Medical CenterResidency, Pathology-Anatomic and Clinical, 1986 - 1987
- Boston University Medical CenterResidency, Internal Medicine, 1983 - 1986
- Yale School of MedicineClass of 1983
- Amherst CollegeA.B., Biology, 1979
Certifications & Licensure
- MA State Medical License 1986 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- DOD Breast Cancer Idea Award 2001
- Career Development Award American Society of Clinical Oncology, 1998
- Leukemia Society of America Translational Research Award 1997
- Join now to see all
Clinical Trials
- Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2004 Apr 01
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
- Everolimus in Treating Cutaneous T-cell Lymphoma Start of enrollment: 2012 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsAnti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes.Chenjia Xu, Arlene R. Wyman, Manal A. Alaamery, Shannon A. Argueta, F. Douglas Ivey
International Immunopharmacology. 2016-09-01 - 81 citationsp130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor.Takaya Gotoh, Dongpo Cai, Xuejun Tian, Larry A. Feig, Adam Lerner
The Journal of Biological Chemistry. 2000-09-29 - 368 citationsBrentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, Youn H. Kim, Steven M. Horwitz, Reinhard Dummer, Julia Scarisbrick
Lancet. 2017-08-05
Journal Articles
- AND-34/BCAR3 augments the ability of p130Cas to bind the Src SH3 domain in a BCAR3-p130Cas complex-dependent mannerMakkinje A, VandenBorre P, Near RI, Patel P and Lerner A, J. Biol. Chem, 1/1/2012
- Primary cutaneous CD56 positive lymphoma: a diagnostic conundrum in an unusual case of lymphomaSchieke SM, Sharaf M, Lerner A, Runger T, Mahalingam M, J. Cutan. Pathol, 1/1/2012
- Complete response of metastatic hidradenocarcinoma to capecitabineLerner A, Beckford A, Ugent S, Goldberg L, Jalisi S and Demierre MF, Archives of Derm, 1/1/2011
- Join now to see all
Books/Book Chapters
Press Mentions
- Matthew Kulke, MD, Joins BUMCNovember 21st, 2017
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: